Stallergenes gains U.S. FDA approval for Oralair allergy drug
[Reuters] – France’s Stallergenes said on Tuesday it received the U.S. Food and Drug Administration’s green light to sell its immunotherapy pill Oralair for treating grass allergies. The drug is a fast-dissolving tablet to be placed under the tongue that moreView todays social media effects on MRKView the latest stocks trending across Twitter. Click to view dashboardSee who Merck is […]